Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies

References

• Lipworth BJ. Optimizing bronchodilator therapy for COPD. Chest. 2001;119(6):1628–1630.
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD); 2015 [updated 2015; cited 2015 Nov 23]. Available from: www.goldcopd.org
   Google Scholar
• Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Approval letter NDA 20-692/S-016. Serevent Diskus (salmeterol xinafoate) inhalation powder; 2002 [cited 2015 Nov 23]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20692s016ltr.pdf
   Google Scholar
• Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115(4):957–965.
   PubMed Web of Science ®Google Scholar
• The European Agency for the Evaluation of Medicinal Products Post-authorisation Evaluation of Medicines for Human Use. Committee for propietary medicinal products (CPMP) opinion following an article 7(5) referral: salmeterol and fluticasone propionate. Opinion. London, Report No.: CPMP/1327/03; [cited 2015 Nov 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Salmeterol_7_5/WC500013825.pdf
   Google Scholar
• U.S. Food and Drug Administration. Approval package for: application number: NDA 21-077/S-003. Report No.: NDA 21-077/S-003; 2003 Nov 11 [cited 2015 Nov 23]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021077_s003_advair_diskus.pdf
   Google Scholar
• U.S. Food and Drug Administration. Supplement letter Advair Diskus (fluticasone propionate and salmeterol xinafoate inhalation powder) 250/50 mcg. NDA 21-077/S-029. 2008 Apr 30 [cited 2011 Oct 26]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021077029ltr.pdf
   Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555.
   PubMed Web of Science ®Google Scholar
• GOLD. Executive summary: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2009 [updated 2009; cited 2015 Nov 23]. Available from: http://goldcopd.org/
   Google Scholar
• Restrepo RD, Tate A, Coquat J. Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14(14):1993–2002.
   PubMed Web of Science ®Google Scholar
• Nannini L, Lasserson TJ, Poole P. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003;(4):CD003794.
   Google Scholar
• Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004;(3):CD003794.
   Google Scholar
• Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(4):CD003794.
   Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009;136(4):1029–1038.
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(11):CD003794.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Eng J Med. 2007;356(8):775–789.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Advair Diskus prescribing information; [revised 2008 Apr; cited 2015 Nov 23]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021077s029lbl.pdf
   Google Scholar
• FitzGerald JM, Haddon JM, Bradly-Kennedy C, et al. Resource use study in COPD (RUSIC): a prospective study to, quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J. 2007;14(3):145–152.
   PubMed Web of Science ®Google Scholar
• Marton JP, Boulanger L, Friedman M, et al. Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective. Respir Med. 2006;100(6):996–1005.
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respir Med. 2008;102(9):1248–1256.
   PubMed Web of Science ®Google Scholar
• Punekar YS, Shukla A, Mullerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65–73.
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(9):98.
   Google Scholar
• Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(5):CD007891.
   Google Scholar
• Mapel DW, Schum M, Lydick E, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics. 2010;28(9):733–749.
   PubMed Web of Science ®Google Scholar
• Rutten-van Molken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics. 2012;30(4):271–302.
   PubMed Web of Science ®Google Scholar
• Simoens S. Cost-effectiveness of pharmacotherapy for COPD in ambulatory care: a review. J Eval Clin Pract. 2013;19(6):1004–1011.
   PubMed Web of Science ®Google Scholar
• Castaldi PJ, Rogers WH, Safran DG, et al. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. Chest. 2010;138(3):614–620.
   PubMed Web of Science ®Google Scholar
• Semark B, Engstrom S, Brudin L, et al. Factors influencing the prescription of drugs of different price levels. Pharmacoepidemiol Drug Saf. 2013;22(3):286–293.
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kelly SM, Lam SY, et al. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J. 2012;19(5):319–324.
   PubMed Web of Science ®Google Scholar
• Essue B, Kelly P, Roberts M, et al. We can’t afford my chronic illness! The out-of-pocket burden associated with managing chronic obstructive pulmonary disease in western Sydney, Australia. J Health Serv Res Policy. 2011;16(4):226–231.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Dalal AA, Mapel D. Changes in COPD demographics and costs over 20 years. J Med Econ. 2012;15(6):1176–1182.
   PubMedGoogle Scholar
• Stuart BC, Simoni-Wastila L, Zuckerman IH, et al. Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary disease. Am J Geriatr Pharmacother. 2010;8(5):441–453.
   PubMedGoogle Scholar
• Gross NJ. Tiotropium bromide. Chest. 2004;126(6):1946–1953.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther. 2007;20(5):495–502.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease. Drugs. 2009;69(11):1459–1470.
   PubMed Web of Science ®Google Scholar
• Moen MD. Indacaterol: in chronic obstructive pulmonary disease. Drugs. 2010;70(17):2269–2280.
   PubMed Web of Science ®Google Scholar
• Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741–753.
   PubMed Web of Science ®Google Scholar
• Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(9):CD010509.
   Google Scholar
• Segreti A, Calzetta L, Rogliani P, et al. Umeclidinium for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2014;8(6):665–671.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Rogliani P, et al. β2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187(7):690–696.
   PubMed Web of Science ®Google Scholar
• McKeage K. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74(13):1509–1522.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Roberts MH. Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting β-agonists: a review of comparative effectiveness research. Drugs. 2014;74(7):737–755.
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(4):CD006826.
   Google Scholar
• Mensing M, Aalbers R. Comparison and optimal use of fixed combinations in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(2):107–116.
   PubMedGoogle Scholar
• Hanania NA. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther. 2008;21(3):540–550.
   PubMed Web of Science ®Google Scholar
• Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med. 2009;7:2.
   PubMed Web of Science ®Google Scholar
• Kliber A, Lynd LD, Sin DD. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res. 2010;11:56.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Raphiou I, Hurley JS, et al. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:165–178.
   PubMedGoogle Scholar
• Cave AC, Hurst MM. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Pharmacol Ther. 2011;130(2):114–143.
   PubMed Web of Science ®Google Scholar
• Spencer S, Karner C, Cates CJ, et al. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(12):CD007033.
   Web of Science ®Google Scholar
• Nannini LJ, Poole P, Milan SJ, et al. Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(11):CD003794.
   Google Scholar
• Restrepo RD, Tate A, Coquat J. Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013;14(14):1993–2002.
   PubMed Web of Science ®Google Scholar
• Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;(3):CD010844.
   PubMed Web of Science ®Google Scholar
• Oba Y, Lone NA. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:469–479.
   PubMed Web of Science ®Google Scholar
• Fritscher L, Chapman KR. Seretide: a pharmacoeconomic analysis. J Med Econ. 2008;11(3):555–570.
   PubMedGoogle Scholar
• Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis. 2008;3(1):71–88.
   PubMedGoogle Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61.
   PubMedGoogle Scholar
• Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172–1177.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13(3):277–288.
   PubMed Web of Science ®Google Scholar
• Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6(1):51–59.
   Google Scholar
• Shemilt I CCEMG-EPPI-Centre cost converter; version 1.4; [cited 2015 Oct 28]. Available from: http://eppi.ioe.ac.uk/costconversion/default.aspx
   Google Scholar
• International Monetary Fund (IMF) exchange rate query tool; [cited 2015 Oct 28]. Available from: http://www.imf.org/external/np/fin/ert/GUI/Pages/CountryDataBase.aspx
   Google Scholar
• Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–637.
   PubMed Web of Science ®Google Scholar
• Dal NR, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2(2):169–176.
   PubMedGoogle Scholar
• Earnshaw SR, Wilson MR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009;103(1):12–21.
   PubMed Web of Science ®Google Scholar
• Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care. 2009;15(4):226–232.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2010;35(3):532–539.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011;14(8):1039–1047.
   PubMed Web of Science ®Google Scholar
• Guillermo Ariza J, Thuresson P-O, Machnicki G, et al. The cost-effectiveness and budget impact of introducing indacaterol into the Colombian health system. Value Health Reg Issues. 2012;1(2):165–171.
   Google Scholar
• Price D, Keininger D, Costa-Scharplatz M, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med. 2014;108(12):1786–1793.
   PubMed Web of Science ®Google Scholar
• Rascati KL, Akazawa M, Johnsrud M, et al. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of texas medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther. 2007;29(6):1203–1213.
   PubMed Web of Science ®Google Scholar
• Akazawa M, Hayflinger DC, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care. 2008;14(7):438–448.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Akazawa M, Dalal A, et al. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 mu g/salmeterol 50 mu g compared with ipratropium for chronic obstructive pulmonary disease in older adults. Am J Geriatr Pharmacother. 2008;6(3):138–146.
   PubMedGoogle Scholar
• Delea TE, Hagiwara M, Dalal AA, et al. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin. 2009;25(1):1–13.
   PubMed Web of Science ®Google Scholar
• Dalal AA, St Charles M, Petersen HV, et al. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. Int J Chron Obstruct Pulmon Dis. 2010;5:179–187.
   PubMedGoogle Scholar
• Cao Z, Zou KH, Baker CL, et al. Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy. J Med Econ. 2011;14(2):147–158.
   PubMedGoogle Scholar
• Dalal AA, Roberts MH, Petersen HV, et al. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:13–22.
   Web of Science ®Google Scholar
• Roberts MH, Dalal AA. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching. Int J Chron Obstruct Pulmon Dis. 2012;7(1):221–233.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah M, D’Souza AO, et al. COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol combination versus other maintenance therapies. Am J Manag Care. 2011;17(3):e55–e65.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 μg/50 μg combination versus tiotropium in commercially insured patients with COPD. Manag Care. 2011;20(8):46–50, 3–5.
   PubMedGoogle Scholar
• Halpern R, Baker CL, Su J, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence. 2011;5:375–388.
   PubMed Web of Science ®Google Scholar
• Roberts M, Mapel D, Petersen H, et al. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769–776.
   PubMedGoogle Scholar
• Dalal AA, Shah MB, D’Souza AO, et al. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. Respir Res. 2012;13:41.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah M, D’Souza AO, et al. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy. Respir Med. 2012;106(6):829–837.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah M, D’Souza AO, et al. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population. Int J Chron Obstruct Pulmon Dis. 2012;7:11–19.
   PubMed Web of Science ®Google Scholar
• Roggeri A, Micheletto C, Roggeri DP. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study. Int J Chron Obstruct Pulmon Dis. 2014;9:569–576.
   PubMed Web of Science ®Google Scholar
• Altaf M, Zubedi AM, Nazneen F, et al. Cost-effectiveness analysis of three different combinations of inhalers for severe and very severe chronic obstructive pulmonary disease patients at a tertiary care teaching hospital of South India. Perspect Clin Res. 2015;6(3):150–158.
   PubMedGoogle Scholar
• Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–162.
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273(6):584–594.
   PubMed Web of Science ®Google Scholar
• Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler): National Institute for Health and Care Excellence, NICE advice Report No.: ESNM33; 2014 [cited 2015 Nov 21]. Available from: https://www.nice.org.uk/advice/esnm33/chapter/Key-points-from-the-evidence
   Google Scholar
• Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695–708.
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD); 2014 [updated 2014; cited 2015 Nov 23]. Available from: www.goldcopd.org
   Google Scholar
• Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6(5):320–329.
   PubMedGoogle Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456.
   PubMed Web of Science ®Google Scholar
• Cope S, Capkun-Niggli G, Gale R, et al. Comparative efficacy of indacaterol 150 mug and 300 mug versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease–a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2011;6:329–344.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–1258.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006;3(7):619–623.
   PubMedGoogle Scholar
• Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 mu g) or salmeterol (50 mu g) on COPD exacerbations. Respir Med. 2008;102(8):1099–1108.
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17(2):157–173.
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255.
   PubMed Web of Science ®Google Scholar
• Halpin DM. Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice. Prim Care Respir J. 2010;19(2):170–179.
   PubMedGoogle Scholar
• Chapman KR, Bergeron C, Bhutani M, et al. Do we know the minimal clinically important difference (MCID) for COPD exacerbations? COPD. 2013;10(2):243–249.
   PubMedGoogle Scholar
• D’Agostino R. Estimating treatment effects using observational data. JAMA. 2007;297:314–316.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
   Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679.
   PubMed Web of Science ®Google Scholar
• Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health. 2000;21:121–145.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10(2):110–120.
   Google Scholar
• Hillas G, Perlikos F, Tsiligianni I, et al. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109.
   PubMed Web of Science ®Google Scholar
• Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology. 2015;20(8):1160–1171.
   PubMed Web of Science ®Google Scholar
• Wang Y, Stavem K, Dahl FA, et al. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int J Chron Obstruct Pulmon Dis. 2014;9:99–105.
   PubMed Web of Science ®Google Scholar
• Menezes AM, Montes De Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297–304.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Roberts MH. New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics. 2012;30(10):869–885.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses–United States, 2000-2004. MMWR 2008;57(45):1226–1228.
   PubMedGoogle Scholar
• Foster TS, Miller JD, Marton JP, et al. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD. 2006;3(4):211–218.
   PubMedGoogle Scholar
• Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest. 2002;122(6):1994–2002.
   PubMed Web of Science ®Google Scholar
• Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S43–S50.
   PubMed Web of Science ®Google Scholar
• Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med. 2003;97(3):212–220.
   PubMed Web of Science ®Google Scholar
• Neumann P, Fang C-H, Cohen J. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. PharmacoEconomics. 2009;27(10):861–872.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Rosen AB, Greenberg D, et al. Can we better prioritize resources for cost-utility research? Med Decis Making. 2005;25(4):429–436.
   PubMed Web of Science ®Google Scholar
• Dunn AG, Coiera E. Should comparative effectiveness research ignore industry-funded data? J Comp Eff Res. 2014;3(4):317–320.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl. 2003;21:29s–35s.
   Google Scholar
• Hoogendoorn M, Feenstra TL, Asukai Y, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health. 2014;17(5):525–536.
   PubMed Web of Science ®Google Scholar
• Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy. 2008;86(2–3):129–141.
   PubMed Web of Science ®Google Scholar
• Brousselle A, Lessard C. Economic evaluation to inform health care decision-making: promise, pitfalls and a proposal for an alternative path. Soc Sci Med. 2011;72(6):832–839.
   PubMed Web of Science ®Google Scholar
• King S The best selling drugs of all time; Humira joins the elite. Forbes. 2013 [cited 2015 Dec 5]. Available from: www.forbes.com
   Google Scholar
• IMS Health. Top 20 global products 2014; [cited 2015 Dec 5]. Available from: http://www.imshealth.com/files/web/Corporate/News/Top-Line%20Market%20Data/2014/Top_20_Global_Products_2014.pdf
   Google Scholar
• Celli BR, Decramer M, Wedzicha JA, et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Resp J. 2015;45(4):879–905.
   PubMed Web of Science ®Google Scholar
• Berger ML, Doban V. Big data, advanced analytics and the future of comparative effectiveness research. J Comp Eff Res. 2014;3:167–176.
   PubMed Web of Science ®Google Scholar
• Young SD. Behavioral insights on big data: using social media for predicting biomedical outcomes. Trends Microbiol. 2014;22(11):601–602.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA. 1994;272(19):1497–1505.
   PubMed Web of Science ®Google Scholar
• Lindberg A, Larsson L-G, Rönmark E, et al. Decline in FEV1 in relation to incident chronic obstructive pulmonary disease in a cohort with respiratory symptoms. COPD. 2007;4(1):5–13.
   PubMedGoogle Scholar